If you or your loved one is considering treatment options for an opioid-free recovery journey, it may be time to discuss VIVITROL with a healthcare provider.


  • Opioid antagonist
  • HCP-administered
  • Once-monthly injection
  • Used with counseling
  • Non-addictive
  • Not a narcotic
  • Requires opioid detox

Before starting VIVITROL, you must be opioid-free for a minimum of 7 to 14 days to avoid sudden opioid withdrawal.


When used as part of a treatment plan that includes counseling, VIVITROL prevents relapse to opioid dependence after opioid detox.1

A 6-month, double-blind, placebo-controlled, randomized clinical study compared opioid-dependent patients treated with either a placebo and counseling (n=124) or VIVITROL and counseling (n=126).

90% opioid-free weeks


The median patient reported 90% opioid-free weeks, compared to 35% receiving the placebo.
Data was not collected during weeks 1-4 of trail to allow for stabilization of abstinence.

55% decrease in self-reported opioid craving


Patients given VIVITROL had a 55% decrease in self-reported opioid craving from baseline (-10.1 points) vs 3% increase for patients given placebo (+0.7 points).

17 times less likely to relapse


Only 1 patient on VIVITROL (<1%) discontinued due to positive naloxone challenge, indicating physical dependence had been re-established, compared to 17 patients on placebo (14%, P<0.0001.)

Patients taking VIVITROL® stayed in treatment >168 days vs 96 days for those taking the placebo.


When the study ended at 168 days, more than half of VIVITROL patients were still in the study; while half of placebo patients dropped out by day 96.

*Confirmed abstinence was defined as a negative urine drug test for opioids and no self-reported opioid use for all weekly visits. Craving was measured by self-reported “need for opioids” using a visual analog scale.


Is there a risk of opioid overdose with VIVITROL?3

Yes. One serious side effect of VIVITROL is the risk of opioid overdose. Using opioids, even in amounts that you used before VIVITROL treatment, can lead to accidental overdose, serious injury, coma, or death.

  • Do not take large amounts of opioids or try to overcome the opioid-blocking effects of VIVITROL.
  • Do not use opioids in amounts that you used before VIVITROL treatment. You may even be more sensitive to lower amounts of opioids:
  • After detox
  • When your next VIVITROL dose is due
  • If you miss a dose of VIVITROL
  • After you stop VIVITROL treatment

Get emergency medical help right away if you:

  • have trouble breathing
  • become very drowsy with slowed breathing
  • have slow, shallow breathing (little chest movement with breathing)
  • feel faint, dizzy, confused or have other unusual symptoms.

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.

Is there a risk of severe reactions at the injection site with VIVITROL?

Yes. One serious side effect of VIVITROL is severe reactions at the site of the injection, including tissue death. Some injection site reactions have required surgery. VIVITROL must be injected by a healthcare provider. Call your healthcare provider right away if you notice any of the following at your injection site:

  • Intense pain
  • The area feels hard
  • Swelling
  • Lumps
  • Blister
  • An open wound
  • A dark scab

Tell your healthcare provider about any injection site reaction that concerns you, gets worse over time, or does not get better by two weeks after the injection.

Is there a risk of sudden opioid withdrawal when starting VIVITROL?

Yes. One serious side effect of VIVITROL is sudden opioid withdrawal. You must stop taking any opioids or opioid-containing medications, including buprenorphine or methadone, for at least 7 to 14 days before starting VIVITROL. If your healthcare provider decides that you don’t need to complete detox first, he or she may give you VIVITROL in a medical facility that can treat sudden opioid withdrawal. Sudden opioid withdrawal can be severe and may require hospitalization.

VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, severe reaction at the injection site and sudden opioid withdrawal.
See Important Safety Information below. Discuss all benefits and risks with a healthcare provider. See Prescribing Information and Medication Guide.


  1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc; rev September 2019.
  2. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513.
  3. VIVITROL [medication guide]. Waltham, MA: Alkermes, Inc; rev July 2019.

Terms and Conditions

*Eligibility for Alkermes-Sponsored Co-pay Savings. This offer is only available to patients 18 years or older, with a prescription consistent with the Prescribing Information and the patient is not enrolled in, or covered by, any local, state, federal or other government program that pays for any portion of medication costs, including but not limited to Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care and Alternative Benefit Plans under the Affordable Care Act; Medigap; VA; DOD; TRICARE; or a residential correctional program.
Additional Terms of Use: This offer is not conditioned on any past, present, or future purchase, including refills. Alkermes reserves the right to rescind, revoke, or amend this offer, program eligibility, and requirements at any time without notice. This offer is limited to one per patient, may not be used with any other offer, is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade. Void where prohibited by law. Program Administrator or its designee will have the right upon reasonable prior written notice, during normal business hours, and subject to applicable law, to audit compliance with this program.